Hexavalent Vaccines in India: Current Status

被引：7

作者：

Chitkara, Amar Jeet ^{[1
]}

Parikh, Raunak ^{[2
]}

Mihalyi, Attila ^{[3
]}

Kolhapure, Shafi ^{[2
]}

机构：

[1] Max Superspecial Hosp, Dept Pediat, Delhi, India

[2] Glaxo Smith Kline Biol SA, Mumbai, Maharashtra, India

[3] Glaxo Smith Kline Biol SA, Wavre, Belgium

来源：

INDIAN PEDIATRICS | 2019年 / 56卷 / 11期

关键词：

Combination vaccines; Acellular Vaccine; Immunization; Pertussis; PNEUMOCOCCAL CONJUGATE VACCINE; ACELLULAR PERTUSSIS-VACCINE; 3-DOSE PRIMARY VACCINATION; DTPA-HBV-IPV/HIB; ROUTINE INFANT; B VACCINE; COMBINATION VACCINES; IMMUNOGENICITY; SAFETY; IMMUNIZATION;

D O I：

10.1007/s13312-019-1651-y

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Hexavalent vaccines containing diphtheria, tetanus, pertussis, Haemophilus influenzae type b, poliomyelitis, and hepatitis B virus antigens have the potential to be used for the primary series in India (6, 10, 14 weeks of age) and the toddler booster dose. Three hexavalent vaccines are available in India: DTwP-Hib/HepB-IPV (wP-hexa), DTaP-IPV-HB-PRPT(2aP-hexa), and DTaP-HBV-IPV/Hib (3aP-hexa). In the three published phase-3 Indian studies, pertussis 'vaccine response' rates 1 month after a 6-10-14-week primary series were 68.4-75.7% for wP-hexa, 93.8-99.3% for 2aP-hexa, and 97.0-100% for 3aP-hexa; seroprotection rates for the other five antigens were 88.2-100%, 49.6-100%, and 98.6-100%, respectively. Studies outside India show: good immunogenicity/safety after boosting dosing; immune persistence to age 4.5 years (2aP-hexa), 7-9 years (3aP-hexa) (all antigens), and 9-10 and 14-15 years, respectively (hepatitis B); and successful co-administration with other vaccines. Hexavalent vaccines could reduce the number of injections, simplify vaccination schedules, and improve compliance.

引用

页码：939 / 950

页数：12

共 65 条

[11] The pertussis enigma: reconciling epidemiology, immunology and evolution [J].

de Celles, Matthieu Domenech ;

Magpantay, Felicia M. G. ;

King, Aaron A. ;

Rohani, Pejman .

PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2016, 283 (1822)

[12] PERISCOPE: road towards effective control of pertussis [J].

Diavatopoulos, Dimitri A. ;

Mills, Kingston H. G. ;

Kester, Kent E. ;

Kampmann, Beate ;

Silerova, Marcela ;

Heininger, Ulrich ;

van Dongen, Jacques J. M. ;

van der Most, Robbert G. ;

Huijnen, Martijn A. ;

Siena, Emilio ;

Mielcarek, Nathalie ;

Ochs, Martina M. ;

Denoel, Philippe ;

Berbers, Guy ;

Buisman, Annemarie M. ;

de Jonge, Marien I. ;

Fenwick, Craig ;

Gorringe, Andrew ;

He, Qiushui ;

Kelly, Dominic ;

Le Grand, Roger ;

Locht, Camille ;

Mascart, Francoise ;

Mertsola, Jussi ;

Orfao, Alberto ;

Pantaleo, Giuseppe ;

Pollard, Andrew J. ;

Preston, Andrew ;

Read, Robert ;

Sebo, Peter ;

van Els, Cecile ;

Vecerek, Branislav ;

Londono-Hayes, Patricia ;

de Groot, Ronald .

LANCET INFECTIOUS DISEASES, 2019, 19 (05) :E179-E186

[13]

Dolhain J, 2017, INTEGRATION HEPATITI

[14]

Dowling David J, 2018, Immunohorizons, V2, P185, DOI 10.4049/immunohorizons.1700063

[15] Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers [J].

Esposito, Susanna ;

Tansey, Susan ;

Thompson, Allison ;

Razmpour, Ahmad ;

Liang, John ;

Jones, Thomas R. ;

Ferrera, Giuseppe ;

Maida, Alessandro ;

Bona, Gianni ;

Sabatini, Caterina ;

Pugni, Lorenza ;

Emini, Emilio A. ;

Gruber, William C. ;

Scott, Daniel A. ;

Principi, Nicola .

CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (06) :1017-1026

[16] Challenges of interpreting epidemiologic surveillance pertussis data with changing diagnostic and immunization practices: the case of the state of Sao Paulo, Brazil [J].

Fernandes, Eder Gatti ;

Christovam Sartori, Ana Marli ;

de Soarez, Patricia Coelho ;

Carvalhanas, Telma Regina M. P. ;

Rodrigues, Marcela ;

Dutilh Novaes, Hillegonda Maria .

BMC INFECTIOUS DISEASES, 2018, 18

[17]

Gatchalian SBL, 2007, PHILIPP J PEDIATR, V56, P153

[18]

GlaxoSmithKline UK, INF HEX SUMM PROD CH

[19] Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules A Randomized Controlled Trial [J].

Gossger, Nicoletta ;

Snape, Matthew D. ;

Yu, Ly-Mee ;

Finn, Adam ;

Bona, Gianni ;

Esposito, Susanna ;

Principi, Nicola ;

Diez-Domingo, Javier ;

Sokal, Etienne ;

Becker, Birgitta ;

Kieninger, Dorothee ;

Prymula, Roman ;

Dull, Peter ;

Ypma, Ellen ;

Toneatto, Daniela ;

Kimura, Alan ;

Pollard, Andrew J. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (06) :573-582

[20]

GSK, 2016, IMM SAF STUD GLAXOSM

← 1 2 3 4 5 6 7 →